Expanded access
View article: FAIRsharing record for: Long-Acting Therapeutics Patents and Licences Database
FAIRsharing record for: Long-Acting Therapeutics Patents and Licences Database Open
This FAIRsharing record describes: LAPaL is a repository for information on long-acting (LA) technologies patents and licences. As of Sep 2025, it comprises 37 long-acting platform technologies and 50 LA formulations with many potential ap…
View article: LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT
LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT Open
Lenacapavir (GS‑6207, brand Sunlenca/Yeztugo) is an anti-Retroviral drug developed by Gilead Sciences as one of very first class of HIV capsid inhibitor. Its discovery has been built upon decades of NIH (National Institute of health)-funde…
View article: LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT
LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT Open
Lenacapavir (GS‑6207, brand Sunlenca/Yeztugo) is an anti-Retroviral drug developed by Gilead Sciences as one of very first class of HIV capsid inhibitor. Its discovery has been built upon decades of NIH (National Institute of health)-funde…
View article: Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States
Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States Open
These findings highlight the significant uncompensated burden placed on oncology practices, raising concerns about how non-reimbursed tasks may affect patient care, staff retention, and the financial sustainability of these practices.
View article: Geospatial and Temporal Trends in Neonatal Mortality: Savannah Region, Ghana, 2020-2024
Geospatial and Temporal Trends in Neonatal Mortality: Savannah Region, Ghana, 2020-2024 Open
Introduction Despite progress in reducing child mortality globally, neonatal mortality remains a concern in Ghana, where preventable causes and regional disparities persist. Some regions experience rates twice as high as others, highlighti…
View article: Educational and Equity Implications of Biomarker Testing and Targeted Therapy Access in NSCLC: Insights from the NIH All of Us Research Program
Educational and Equity Implications of Biomarker Testing and Targeted Therapy Access in NSCLC: Insights from the NIH All of Us Research Program Open
Precision oncology in non-small cell lung cancer (NSCLC) depends on biomarker testing and access to targeted therapies. However, disparities in testing and treatment highlight critical educational needs for patients, providers, and health …
View article: Suppl Table S2 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Suppl Table S2 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency Open
Results of time-dependent co-variate and landmark analyses at time-points 3 and 6 months of the trial
View article: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma Open
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
View article: Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Open
To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.
View article: FDA greenlights retifanlimab combo and monotherapy for advanced anal cancer: a new era in anal squamous cell carcinoma treatment
FDA greenlights retifanlimab combo and monotherapy for advanced anal cancer: a new era in anal squamous cell carcinoma treatment Open
The occurrence of anal squamous cell carcinoma (ASCC), predominantly driven by persistent HPV infection, is increasing all over the world. The phase-3 POD1UM trial assessed adding the PD-1 inhibitor retifanlemab to standard Carboplatin-pac…
View article: Real-World Outcomes of Lower Lenvatinib Doses in Advanced Neuroendocrine Tumors: A Multinational Retrospective Study
Real-World Outcomes of Lower Lenvatinib Doses in Advanced Neuroendocrine Tumors: A Multinational Retrospective Study Open
Objective Neuroendocrine tumors (NET) are heterogeneous neoplasms with increasing incidence and limited treatment options for advanced, progressive disease. Lenvatinib, a multitargeted TKI, demonstrat-ed high efficacy but substantial toxic…
View article: Access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practise
Access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practise Open
Introduction Rabies remains a preventable yet fatal disease that continues to claim lives in low- and middle-income countries due to barriers in accessing post-exposure prophylaxis (PEP). With Gavi, the Vaccine Alliance, now supporting PEP…
View article: Access to hypertension services and health-seeking experiences in rural Coastal Kenya: A qualitative study
Access to hypertension services and health-seeking experiences in rural Coastal Kenya: A qualitative study Open
Globally, hypertension causes 10.8 million deaths annually. However, in Kenya, like in other low-and middle-income countries, access to hypertension care remains limited and inequitable. Understanding patients’ journeys in accessing care a…
View article: Attrition rate of antiretroviral therapy and its influencing factors among Chinese people living with HIV/AIDS: a meta-analysis and system review
Attrition rate of antiretroviral therapy and its influencing factors among Chinese people living with HIV/AIDS: a meta-analysis and system review Open
Our meta-analysis indicates that ART attrition among PWH in China is relatively high and influenced by multiple factors. Accelerating ART initiation, optimizing medication access and adverse-event management, and strengthening social and f…
View article: Outcomes and toxicity of concomitant radioimmunotherapy following PD-1 blockade for locally advanced and metastatic cutaneous squamous cell carcinoma
Outcomes and toxicity of concomitant radioimmunotherapy following PD-1 blockade for locally advanced and metastatic cutaneous squamous cell carcinoma Open
Introduction Immune checkpoint inhibitors (ICI) effectively treat advanced cutaneous squamous cell carcinoma (cSCC), yet some patients continue to have disease progression. Combining radiation therapy (RT) with ICI represents a potential t…
View article: Early Post-Approval Experience of The Selective Cytopheretic Device Surveillance Registry for Pediatric AKI Requiring Kidney Replacement Therapy
Early Post-Approval Experience of The Selective Cytopheretic Device Surveillance Registry for Pediatric AKI Requiring Kidney Replacement Therapy Open
Background The selective cytopheretic device for pediatrics (SCD-PED) was granted a Humanitarian Device Exemption (HDE) in 2024 by United States Food and Drug Administration (FDA) for treatment of critically ill children weighing ≥ 10 kilo…
View article: Development of a Low-Barrier, Reimbursable Take-Home Naloxone Program at a Regional Health System
Development of a Low-Barrier, Reimbursable Take-Home Naloxone Program at a Regional Health System Open
Introduction: Take-home naloxone (THN) programs in emergency departments (ED) can reduce opioid overdose deaths by providing naloxone directly to at-risk patients before discharge. However, sustainable models that integrate reimbursement a…
View article: Global Biologics Market: Definition, Scope, and Growth Outlook
Global Biologics Market: Definition, Scope, and Growth Outlook Open
The biologics market encompasses therapeutic products derived from living organisms, including advanced treatments such as monoclonal antibodies, vaccines, and gene or cell therapies. It is rapidly expanding due to rising demand for target…
View article: Geographical disparities for liver transplantation access in Mexico
Geographical disparities for liver transplantation access in Mexico Open
BACKGROUND Liver disease is a major cause of mortality in Mexico. Liver transplantation (LT) remains severely limited, and there are no reports on equity of access. AIM To analyze geographical disparities in LT access in Mexico. METHODS LT…
View article: Global Biologics Market: Definition, Scope, and Growth Outlook
Global Biologics Market: Definition, Scope, and Growth Outlook Open
The biologics market encompasses therapeutic products derived from living organisms, including advanced treatments such as monoclonal antibodies, vaccines, and gene or cell therapies. It is rapidly expanding due to rising demand for target…
View article: FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma
FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma Open
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory mu…
View article: Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study Open
Background Pembrolizumab has demonstrated efficacy in improving disease-free survival (DFS) and overall survival (OS) as adjuvant therapy in clear cell renal cell carcinoma (ccRCC) at a higher risk of recurrence. However, real-world data o…
View article: Supplementary Table S1 from Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor
Supplementary Table S1 from Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor Open
Representativeness of Study Participants
View article: Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)
Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study) Open
Background/Objectives: Anti–PD-1/PD-L1 blockers have revolutionized the treatment landscape of non–small cell lung cancer (NSCLC) lacking oncogene-addicted alterations, particularly in tumors with high PD-L1 expression (tumor proportion sc…
View article: A retrospective molecular epidemiological analysis of EML4-ALK gene fusions in non-small cell lung cancer patients in the Azerbaijani population (2014–2024)
A retrospective molecular epidemiological analysis of EML4-ALK gene fusions in non-small cell lung cancer patients in the Azerbaijani population (2014–2024) Open
Aim This retrospective molecular epidemiological study aimed to determine the prevalence, clinicopathological features, and survival outcomes of ALK gene fusions among patients with non-small cell lung cancer (NSCLC) in Azerbaijan, a count…
View article: Correction: Abemaciclib early access - an Italian experience
Correction: Abemaciclib early access - an Italian experience Open
View article: Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021
Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021 Open
Patients with metastatic uveal melanoma (UM) have a poor prognosis. While long‐term survival data in cutaneous melanoma (CM) are promising, such data are lacking in UM and long‐term survivors are rare. In cases of metastases, the liver is …
View article: Real-world use of pembrolizumab in Germany: patient characteristics and survival
Real-world use of pembrolizumab in Germany: patient characteristics and survival Open
Background: Pembrolizumab was the drug that incurred the highest costs for statutory health insurance in Germany in 2023. Using real-world data, we aimed to characterize patients treated with pembrolizumab in Germany and describe their ove…
View article: Pathway to Creation of the Largest mNSCLC Observational Research Program to Date: Scaling Oncology Research Using Open-Source Methods
Pathway to Creation of the Largest mNSCLC Observational Research Program to Date: Scaling Oncology Research Using Open-Source Methods Open
Title: Pathway to Creation of the Largest mNSCLC Observational Research Program to Date: Scaling Oncology Research Using Open-Source Methods Authors: Daniel Smith, MS [1,2], Jorge Marquez [2], Jeselyn Rhodes, MSPH [2], Xueqiong (Joan) Zhan…
View article: Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL
Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL Open
Introduction: Abrocitinib, an oral, once-daily, JAK1-selective inhibitor, is approved in patients aged ≥12 years at the recommended doses of 100 mg and 200 mg for the treatment of moderate-to-severe atopic dermatitis (AD). JADE REAL (NCT04…